284 related articles for article (PubMed ID: 24484551)
21. [Human papillomavirus prophylactic vaccines: stakes and perspectives].
Hantz S; Alain S; Denis F
Gynecol Obstet Fertil; 2006; 34(7-8):647-55. PubMed ID: 16807045
[TBL] [Abstract][Full Text] [Related]
22. Immune Response Following Quadrivalent Human Papillomavirus Vaccination in Women After Hematopoietic Allogeneic Stem Cell Transplant: A Nonrandomized Clinical Trial.
Stratton P; Battiwalla M; Tian X; Abdelazim S; Baird K; Barrett AJ; Cantilena CR; Childs RW; DeJesus J; Fitzhugh C; Fowler D; Gea-Banacloche J; Gress RE; Hickstein D; Hsieh M; Ito S; Kemp TJ; Khachikyan I; Merideth MA; Pavletic SZ; Quint W; Schiffman M; Scrivani C; Shanis D; Shenoy AG; Struijk L; Tisdale JF; Wagner S; Williams KM; Yu Q; Wood LV; Pinto LA
JAMA Oncol; 2020 May; 6(5):696-705. PubMed ID: 32105293
[TBL] [Abstract][Full Text] [Related]
23. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls.
Medina DM; Valencia A; de Velasquez A; Huang LM; Prymula R; García-Sicilia J; Rombo L; David MP; Descamps D; Hardt K; Dubin G;
J Adolesc Health; 2010 May; 46(5):414-21. PubMed ID: 20413076
[TBL] [Abstract][Full Text] [Related]
24. Long term follow up of persistence of immunity following quadrivalent Human Papillomavirus (HPV) vaccine in immunocompromised children.
MacIntyre CR; Shaw PJ; Mackie FE; Boros C; Marshall H; Seale H; Kennedy SE; Moa A; Chughtai AA; Trent M; O'Loughlin EV; Stormon M
Vaccine; 2019 Sep; 37(37):5630-5636. PubMed ID: 31402238
[TBL] [Abstract][Full Text] [Related]
25. Effective immunization against influenza in pediatric renal transplant recipients.
Edvardsson VO; Flynn JT; Deforest A; Kaiser BA; Schulman SL; Bradley A; Palmer J; Polinsky MS; Baluarte HJ
Clin Transplant; 1996 Dec; 10(6 Pt 1):556-60. PubMed ID: 8996778
[TBL] [Abstract][Full Text] [Related]
26. Quadrivalent human papillomavirus vaccine.
Barr E; Tamms G
Clin Infect Dis; 2007 Sep; 45(5):609-7. PubMed ID: 17682997
[TBL] [Abstract][Full Text] [Related]
27. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study.
Denny L; Hendricks B; Gordon C; Thomas F; Hezareh M; Dobbelaere K; Durand C; Hervé C; Descamps D
Vaccine; 2013 Nov; 31(48):5745-53. PubMed ID: 24091311
[TBL] [Abstract][Full Text] [Related]
28. Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16: a 2-year randomized controlled clinical trial.
Poland GA; Jacobson RM; Koutsky LA; Tamms GM; Railkar R; Smith JF; Bryan JT; Cavanaugh PF; Jansen KU; Barr E
Mayo Clin Proc; 2005 May; 80(5):601-10. PubMed ID: 15887427
[TBL] [Abstract][Full Text] [Related]
29. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18.
Villa LL; Ault KA; Giuliano AR; Costa RL; Petta CA; Andrade RP; Brown DR; Ferenczy A; Harper DM; Koutsky LA; Kurman RJ; Lehtinen M; Malm C; Olsson SE; Ronnett BM; Skjeldestad FE; Steinwall M; Stoler MH; Wheeler CM; Taddeo FJ; Yu J; Lupinacci L; Railkar R; Marchese R; Esser MT; Bryan J; Jansen KU; Sings HL; Tamms GM; Saah AJ; Barr E
Vaccine; 2006 Jul; 24(27-28):5571-83. PubMed ID: 16753240
[TBL] [Abstract][Full Text] [Related]
30. Baseline demographic characteristics of subjects enrolled in international quadrivalent HPV (types 6/11/16/18) vaccine clinical trials.
Paavonen J;
Curr Med Res Opin; 2008 Jun; 24(6):1623-34. PubMed ID: 18435868
[TBL] [Abstract][Full Text] [Related]
31. The prophylactic role for the human papillomavirus quadrivalent vaccine in males.
Yancey AM; Pitlick JM; Forinash AB
Ann Pharmacother; 2010; 44(7-8):1314-8. PubMed ID: 20501891
[TBL] [Abstract][Full Text] [Related]
32. Clinical perspectives on the role of the human papillomavirus vaccine in the prevention of cancer.
Julius JM; Ramondeta L; Tipton KA; Lal LS; Schneider K; Smith JA
Pharmacotherapy; 2011 Mar; 31(3):280-97. PubMed ID: 21361739
[TBL] [Abstract][Full Text] [Related]
33. Assessing human papillomavirus vaccine efficacy and safety.
Hendrix SL
J Am Osteopath Assoc; 2008 Apr; 108(4 Suppl 2):S8-S12. PubMed ID: 18463363
[TBL] [Abstract][Full Text] [Related]
34. Population-based enrolment of adolescents in a long-term follow-up trial of human papillomavirus vaccine efficacy.
Lehtinen M; Idänpään-Heikkilä I; Lunnas T; Palmroth J; Barr E; Cacciatore R; Isaksson R; Kekki M; Koskela P; Kosunen E; Kuortti M; Lahti L; Liljamo T; Luostarinen T; Apter D; Pukkala E; Paavonen J
Int J STD AIDS; 2006 Apr; 17(4):237-46. PubMed ID: 16595046
[TBL] [Abstract][Full Text] [Related]
35. The health and economic impact of cervical cancer screening and human papillomavirus vaccination in kidney transplant recipients.
Wong G; Howard K; Webster A; Chapman JR; Craig JC
Transplantation; 2009 Apr; 87(7):1078-91. PubMed ID: 19352131
[TBL] [Abstract][Full Text] [Related]
36. Immunogenicity and Safety of the 9-Valent Human Papillomavirus Vaccine in Solid Organ Transplant Recipients and Adults Infected With Human Immunodeficiency Virus (HIV).
Boey L; Curinckx A; Roelants M; Derdelinckx I; Van Wijngaerden E; De Munter P; Vos R; Kuypers D; Van Cleemput J; Vandermeulen C
Clin Infect Dis; 2021 Aug; 73(3):e661-e671. PubMed ID: 33373429
[TBL] [Abstract][Full Text] [Related]
37. Bacterially expressed human papillomavirus type 6 and 11 bivalent vaccine: Characterization, antigenicity and immunogenicity.
Pan H; Li Z; Wang J; Song S; Wang D; Wei M; Gu Y; Zhang J; Li S; Xia N
Vaccine; 2017 May; 35(24):3222-3231. PubMed ID: 28483196
[TBL] [Abstract][Full Text] [Related]
38. HIV viral suppression results in higher antibody responses in HIV-positive women vaccinated with the quadrivalent human papillomavirus vaccine.
Money DM; Moses E; Blitz S; Vandriel SM; Lipsky N; Walmsley SL; Loutfy M; Trottier S; Smaill F; Yudin MH; Klein M; Harris M; Cohen J; Wobeser W; Bitnun A; Lapointe N; Samson L; Brophy J; Karatzios C; Ogilvie G; Coutlée F; Raboud J;
Vaccine; 2016 Sep; 34(40):4799-806. PubMed ID: 27544584
[TBL] [Abstract][Full Text] [Related]
39. Safety and immunogenicity of a quadrivalent human papillomavirus vaccine in HIV-infected and HIV-negative adolescents and young adults.
Giacomet V; Penagini F; Trabattoni D; Viganò A; Rainone V; Bernazzani G; Bonardi CM; Clerici M; Bedogni G; Zuccotti GV
Vaccine; 2014 Sep; 32(43):5657-61. PubMed ID: 25149430
[TBL] [Abstract][Full Text] [Related]
40. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses.
David MP; Van Herck K; Hardt K; Tibaldi F; Dubin G; Descamps D; Van Damme P
Gynecol Oncol; 2009 Dec; 115(3 Suppl):S1-6. PubMed ID: 19217149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
